Skip to search formSkip to main contentSkip to account menu

Leukapheresis

Known as: Leukocytapheresis, Leukophereses, Leukocytaphereses 
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

Apheresis (procedure)Therapeutic procedureblood treatment

Narrower (1)

Lymphapheresis
standards characteristics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor
IntroductionMobilization techniques for autologous peripheral blood stem cell (PBSC) collection include chemotherapy followed by… 
Highly Cited
2010
Highly Cited
2010
Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: A prospective cohort study
Background: During active ulcerative colitis (UC), vast numbers of granulocytes, monocytes/macrophages (GM) infiltrate the… 
Highly Cited
2003
Highly Cited
2003
Purification of human natural killer cells using a clinical-scale immunomagnetic method.
BACKGROUND Infection, graft failure, disease relapse, and GvHD are significant adverse events associated with allogeneic BMT… 
Highly Cited
1999
Highly Cited
1999
Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and…
PURPOSE AND METHODS The ability of granulocyte colony-stimulating factor (G-CSF) plus erythropoietin (EPO) treatment was compared… 
Highly Cited
1999
Highly Cited
1999
Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis
AL amyloidosis patients ineligible for dose‐intensive melphalan (200 mg/m2) were enrolled on a phase II trial to be treated with… 
Highly Cited
1994
Highly Cited
1994
Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
The hemopoietic growth factor filgrastim (r-metHu G-CSF) stimulates granulopoiesis after autologous BMT and can also be used as a… 
Review
1988
Review
1988
The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia.
Data were collected from 124 patients with newly diagnosed acute lymphoblastic leukemia (ALL) and WBC greater than 200,000/microL… 
Highly Cited
1987
Highly Cited
1987
Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients
Large numbers of circulating haemopoietic progenitor cells were collected from three patients with lymphoid neoplasms for the… 
Highly Cited
1982
Highly Cited
1982
Purification of human blood monocytes by hypotonic density gradient centrifugation in Percoll.
Highly Cited
1955
Highly Cited
1955
Studies of leukopoiesis: the technique of leukopheresis and the response of myeloid tissue in normal and irradiated dogs.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)